{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:52:27Z","timestamp":1787507547307,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T20:41:43Z","timestamp":1765053703000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial"],"prefix":"10.1016","volume":"25","author":[{"given":"Paul","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3133-5152","authenticated-orcid":false,"given":"Denisa","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Danahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.11.015_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","article-title":"Evidence for airway surface dehydration as the initiating event in CF airway disease","volume":"261","author":"Boucher","year":"2007","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.015_bib0002","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/clinchem\/35.5.726","article-title":"Defective epithelial ion transport in cystic fibrosis","volume":"35","author":"Quinton","year":"1989","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.015_bib0003","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.015_bib0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.015_bib0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physrev.00007.2002","article-title":"Epithelial sodium channel\/degenerin family of ion channels: a variety of functions for a shared structure","volume":"82","author":"Kellenberger","year":"2002","journal-title":"Physiol Rev"},{"issue":"25","key":"10.1016\/j.jcf.2025.11.015_bib0006","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198112173052502","article-title":"Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis","volume":"305","author":"Knowles","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.015_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM199907153410304","article-title":"Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism","volume":"341","author":"Kerem","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.015_bib0008","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/ajrccm\/141.3.605","article-title":"Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy","volume":"141","author":"App","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2025.11.015_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.015_bib0010","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","year":"2020","journal-title":"Mall, MA. Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.015_bib0011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jcf.2025.11.015_bib0012","unstructured":"A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. ClinicalTrials.gov Identifier: NCT02709109. www.Clinicaltrials.gov."},{"issue":"4","key":"10.1016\/j.jcf.2025.11.015_bib0013","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jcf.2022.02.010","article-title":"AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis","author":"Kristensson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00746-2021","article-title":"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study","volume":"59","author":"Goss","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.11.015_bib0015","unstructured":"Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis. ClinicalTrials.gov Identifier: NCT02566044. www.Clinicaltrials.gov."},{"issue":"1","key":"10.1016\/j.jcf.2025.11.015_bib0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcf.2024.06.002","article-title":"ETD001: a novel inhaled ENaC blocker with an extended duration of action in vivo","volume":"24","author":"Danahay","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.015_bib0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/jamp.2013.1037","article-title":"Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411","volume":"27","author":"O'Riordan","year":"2014","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.015_bib0018","doi-asserted-by":"crossref","first-page":"00447","DOI":"10.1183\/23120541.00447-2020","article-title":"First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers","volume":"7","author":"Mackie","year":"2021","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.015_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2013.03.005","article-title":"A review of renal disease in cystic fibrosis","volume":"12","author":"Nazareth","year":"2013","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:37:42Z","timestamp":1781782662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325025299"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}